Neovasc Inc (NVCN) Stock Price History

- Markets
- Tools
  PortfoliosTrack performance, allocation, dividends, and risks
  Stock screenerFilter, compare, and track stocks
  Insiders tradingSee how executives tradeHistogramSee ratios across industries
  Saved screenersMy highlights
- Sign in
- Sign up for free
- 1

Portfolios
Tools
- Stock screener
- Cryptocurrency screener
- Insiders trading
- SEC filings
- Bubbles
- Histogram
Markets

Sign inSign up for free

Market cap	$27.50M
Enterprise value	N/A

Revenue	N/A
EBITDA	N/A
Income	-$33.52
Revenue Q/Q	29.22%
Revenue Y/Y	29.93%

P/E	30.03
Forward P/E	N/A
EV/Sales	2.88
EV/EBITDA	N/A
EV/EBIT	N/A
PEG	N/A
Price/Sales	8.93
P/FCF	N/A
Price/Book	0.53
Book/Share	57.03
Cash/Share	N/A
FCF yield	-4.56%

Employees	54
RPE	N/A

Volume	1.000/N/A
Relative vol.	N/A

EPS	1.00
EPS Q/Q	9.09%
Est. EPS Q/Q	30.40%

Profit margin	N/A
Oper. margin	-989.27%
Gross margin	N/A
EBIT margin	-1,115.69%
EBITDA margin	-1,458.22%

Ret. on assets	-32.95%
Ret. on equity	-78.25%
ROIC	-91.76%
ROCE	-67.63%

Debt/Equity	N/A
Net debt/EBITDA	-0.28
Current ratio	8.44
Quick ratio	8.04

Volatility	1.53%
Beta	0.00

RSI	63.99

Range	$29.43 – $30.07
52 weeks	$30.03 – $30.03
SMA 50	$30 +0.00%
SMA 200	$30 +0.94%

1 year target	$4 -85.38%
Mean Recomm.	N/A

Insider ownership	5.53%
Inst. ownership	10.36%

Shares outst.	2.708M
Shares float	0.000 0.00%
Short % of float	1.02%
Short ratio	5.13

1 year target	$4 -85.38%
Mean Recomm.	N/A

Dividend	N/A
Dividend yield	N/A
Payout ratio	N/A
Payment date	N/A
Ex-dividend date	N/A
Earnings date	N/A

IPO year	2006
Country	Canada

Compare with other stocks

Intraday

5 days

1 month

3 months

6 months

1 year

5 years

All time

Overview
Real-time

Recent Neovasc Inc news

Filter

Tuesday, 11 April 2023
fool	Why Shares of Shockwave Medical Jumped on Tuesday
Monday, 6 March 2023
globenewswire	Neovasc Shareholders Approve Acquisition by Shockwave Medical
Tuesday, 30 August 2022
newsfilecorp	Neovasc to Participate in H.C. Wainwright 24th Annual Global Investment Conference
Thursday, 28 July 2022
newsfilecorp	Neovasc to Report Second Quarter Financial Results on August 11, 2022
Friday, 4 February 2022
newsfilecorp	Independent Publication Reports Neovasc Reducer Demonstrates Cost Savings
Tuesday, 9 November 2021
investorshub.advfn	Neovasc Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Tuesday, 10 August 2021
nasdaq	Neovasc Reports Q2 Loss, Misses Revenue Estimates
Thursday, 3 June 2021
yahoo	Neovasc Inc. Reports Results of Annual General Meeting of Shareholders - Yahoo Finance
Tuesday, 25 May 2021
yahoo	Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
Thursday, 13 May 2021
yahoo	Neovasc to Sponsor Symposium on Reducer at EuroPCR
Thursday, 6 May 2021
yahoo	Neovasc Reports Q1 Loss, Lags Revenue Estimates
Friday, 16 April 2021
yahoo	Neovasc Provides Tiara TA Update
Thursday, 11 March 2021
yahoo	Neovasc Reports Q4 Loss, Misses Revenue Estimates
Thursday, 4 March 2021
yahoo	Neovasc to Report Fourth Quarter and Fiscal Year 2020 Results on March 11, 2021
Tuesday, 2 March 2021
newsfilecorp	Neovasc Comments on Clinical Cardiology Journal Publication
Friday, 5 February 2021
yahoo	Neovasc Comments on Journal of the American Heart Association Publication

Tuesday, 2 February 2021
yahoo	Neovasc Announces 2021 Renewal of German Reimbursem*nt NUB Status 1 Designation for Neovasc Reducer for Treatment of Refractory Angina
Tuesday, 19 January 2021
yahoo	Neovasc Reducer Featured in Three Peer Reviewed Publications Supporting Reducer Therapy
Friday, 15 January 2021
yahoo	Neovasc Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer
Tuesday, 5 January 2021
yahoo	NVCN DEADLINE TODAY: ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Neovasc Inc. Investors of Important Deadline Today in Securities Class Action; Encourages Investors with Losses in Excess of $500K to Contact the Firm - NVCN
Monday, 4 January 2021
benzinga	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Neovasc Inc.
yahoo	NVCN Final Deadline Tomorrow: Rosen, Trusted National Trial Counsel, Reminds Neovasc Inc. Investors of Important January 5 Deadline in Securities Class Action - NVCN
Sunday, 3 January 2021
yahoo	NVCN Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Neovasc Inc. Investors of Class Action and Lead Plaintiff Deadline: January 5, 2021
Friday, 1 January 2021
apnews	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Neovasc, Inc. and Encourages Investors to Contact the Firm
yahoo	NVCN Final Deadline Tuesday: Rosen, A Trusted and Leading Law Firm, Reminds Neovasc Inc. Investors of Important January 5 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - NVCN
Thursday, 24 December 2020
prnewswire	NVCN FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Neovasc Inc. Investors of Important January 5 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - NVCN
Friday, 18 December 2020
yahoo	Rosen, A Global and Leading Law Firm, Reminds Neovasc Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - NVCN
Thursday, 17 December 2020
yahoo	Neovasc Announces Publication of Peer-Reviewed Article in EuroIntervention
Tuesday, 15 December 2020
yahoo	Neovasc Announces First Neovasc Reducer Implants in France
Monday, 14 December 2020
yahoo	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Neovasc Inc. of Class Action Lawsuit and Upcoming Deadline - NVCN
Thursday, 10 December 2020
yahoo	Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
neovasc	Neovasc Announces Closing of US$6.1 Million Registered Direct Offering Priced At-The-Market
Tuesday, 8 December 2020
yahoo	ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Neovasc Inc. Investors of Important January 5 Deadline in Securities Class Action - NVCN
globenewswire	Neovasc Announces US$6.1 Million Registered Direct Offering Priced At-the-Market
Sunday, 6 December 2020
yahoo	Rosen, National Trial Lawyers, Reminds Neovasc Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - NVCN

Filter news

Notable SEC filings of Neovasc Inc
All filingsLast yearly filingFilter


6-K12 Apr 2023	Notice of Change in Corporate Structure
6-K11 Apr 2023	Form 6 K
6-K11 Apr 2023	News Release dated April 11, 2023
6-K31 Mar 2023	Annual Information Formfor the year ended December31, 2022
6-K 9 Mar 2023	Final Order
6-K 7 Mar 2023	Press Release
6-K10 Feb 2023	Notice of Special Meeting of Shareholders
6-K 1 Feb 2023	News Release dated February 1, 2023
6-K27 Jan 2023	Notice of the Meeting and Record Date
6-K18 Jan 2023	Material Change Report, dated January 18, 2023
6-K17 Jan 2023	Arrangement Agreement, dated as of January 16, 2023, between Neovasc Inc. and Shockwave Medical, Inc.

All SEC filingsLast yearly filingFilter filings

Recent call transcripts of Neovasc Inc

Q2 2019 7 August 2019	CEO Fred Colen on Q2 2019 Results - Earnings Call Transcript
Q1 2019 10 May 2019	CEO Fred Colen on Q1 2019 Results - Earnings Call Transcript
Q4 2018 21 March 2019	CEO Fredericus Colen on Q4 2018 Results - Earnings Call Transcript
Q3 2018 14 November 2018	CEO Fredericus Colen on Q3 2018 Results - Earnings Call Transcript
Q2 2018 10 August 2018	CEO Fredericus Colen on Q2 2018 Results - Earnings Call Transcript
Q1 2018 10 May 2018	CEO Fred Colen on Q1 2018 Results - Earnings Call Transcript
Q4 2017 28 March 2018	CEO Fred Colen on Q4 2017 Results - Earnings Call Transcript
Q3 2017 14 November 2017	CEO Alexei Marko on Q3 2017 Results - Earnings Call Transcript
Q2 2017 10 August 2017	CEO Alexei Marko on Q2 2017 Results - Earnings Call Transcript
Q1 2017 10 May 2017	CEO Alexei Marko on Q1 2017 Results - Earnings Call Transcript
Q3 2016 14 November 2016	CEO Alexei Marko on Q3 2016 Results - Earnings Call Transcript

All call transcripts

1,860 people own Neovasc Inc on Robinhood

Powered byRobintrack.

Overall analyst rating

Price target

Current $30.03

Average $4.39

Low $4High $5

Neovasc Inc executives

Insider	Age	Since	Compensation
FredColen		2018	$1,545,230
BillLittle		2019	$779,555
ChristopherClark		2015	$751,863
Fredericus A. Colen(69)Pres, CEO, and Director	69		$664,970
VickiBebeau		2015	$613,040
William Reed Little(49)Chief Operating Officer	49		$452,250
AaronChalekian		2015	$443,675
Christopher Clark B.A., C.A., BA (Honours), PgD, CA(49)CFO and Corp. Sec.	49		$400,458
JohnPanton		2020	$399,564
AlexeiMarko		2017	$320,491
John Christopher Panton(54)Chief Quality Officer	54		$238,223
PaulGeyer		2018	$79,488
StevenRubin(59)Independent Chairman of the Boardsince 2018	59	2018	$79,488
DouglasJanzen		2005	$66,240
NormanRadow		2019
Sarah Marie-Hodgson Gallagher

Neovasc Incwww.neovasc.com

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe.

Health Care>Health Care Equipment
Neovasc Inc, 13562 Maycrest Way, Richmond V6V 2J7, Canada
604 270 4344
Investor relations

Quarterly EPS estimates

Quarterly
Annual

Profit margin

Quarterly
Annual

Debt to assets

Quarterly
Annual

Cash flow

Quarterly
Annual

Quarterly
Annual

XSLX

(in millions USD)	29 Jun 2022	30 Mar 2022	30 Dec 2021	29 Sep 2021
Current assets
Cash	$37.631734	$44.162789	$51.537367	$55.827026
Short term investments
Net receivables	$1.637796	$1.410983	$1.412998	$1.856072
Inventory	$1.265831	$1.402855	$1.480077	$1.622749
Other current assets	$0.102296	$0.130647	$0.136179	$0.174207
Total current assets	$40.898872	$47.948949	$55.218176	$60.218007
Long term investments
Property, plant & equipment	$0.497444	$0.527834	$0.618937	$0.727781
Goodwill
Intangible assets	$0.009721	$0.014582	$0.019443	$0.012383
Other assets	$10.523148	$11.555965	$10.368283	$11.214708
Total assets	$51.929185	$60.04733	$66.224839	$72.172879
Current liabilities
Accounts payable	$1.488599	$1.128739	$1.434357	$1.41398
Short long term debt			$0.07922	$0.300219
Other current liabilities	$0.295096	$0.27981	$0.278041	$0.252292
Total current liabilities	$4.233944	$3.723017	$4.981528	$5.394756
Long term debt	$11.79515	$11.577235	$8.33704	$8.104769
Other liabilities	$0.15534	$0.768322	$0.405508	$0.722293
Minority interest
Total liabilities	$16.361126	$16.275713	$13.996728	$14.571494
Stockholders' equity
Common stock	$441.081488	$440.82712	$439.873457	$439.68536
Retained earnings	-$441.12544	-$432.147842	-$420.116274	-$413.963231
Treasury stock	-$6.229804	-$6.229804	-$7.885024	-$7.981719
Capital surplus	$41.841815	$41.322143	$40.355952	$39.860975
Total stockholder equity	$35.568059	$43.771617	$52.228111	$57.601385
Net tangible assets	$35.558338	$43.757035	$52.208668	$57.589002

(in millions USD)	2021	2020	2019
Current assets
Cash	$51.537367	$12.93586	$5.292833
Short term investments
Net receivables	$1.412998	$1.082906	$0.80246
Inventory	$1.480077	$1.00685	$1.290495
Other current assets	$0.136179	$0.15168	$0.14266
Total current assets	$55.218176	$15.731087	$8.01583
Long term investments
Property, plant & equipment	$0.618937	$1.631058	$1.481485
Goodwill
Intangible assets	$0.019443	$0.002773	$0.006961
Other assets	$10.368283	$0.513301	$0.601564
Total assets	$66.224839	$17.878219	$10.10584
Current liabilities
Accounts payable	$1.434357	$3.705626	$3.993203
Short long term debt	$0.07922	$0.076158	$6.49075
Other current liabilities	$0.278041	$1.721724	$1.412312
Total current liabilities	$4.981528	$7.662568	$14.721558
Long term debt	$8.33704	$7.641253	$8.174919
Other liabilities	$0.405508		$1.186601
Minority interest
Total liabilities	$13.996728	$15.900702	$24.551605
Stockholders' equity
Common stock	$439.873457	$369.775383	$328.460681
Retained earnings	-$420.116274	-$395.227205	-$366.532164
Treasury stock	-$7.885024	-$7.615717	-$6.140507
Capital surplus	$40.355952	$35.045056	$29.766225
Total stockholder equity	$52.228111	$1.977517	-$14.445765
Net tangible assets	$52.208668	$1.974744	-$14.452726

Income statement

Quarterly
Annual

XSLX

(in millions USD)	29 Jun 2022	30 Mar 2022	30 Dec 2021	29 Sep 2021
Revenue
Total revenue	$0.81806	$0.610747	$0.759124	$0.70342
Cost of revenue	$1.176209	$1.359856	$1.460107	$2.956337
Gross profit	-$0.358149	-$0.749109	-$0.700983	-$2.252917
Operating activities
Research & development	$4.341666	$3.26955	$3.608802	$3.477884
Selling, general & administrative	$4.503048	$3.646201	$1.980821	$3.369401
Total operating expenses	$10.020923	$8.275607	$7.04973	$9.803622
Operating income	-$9.202863	-$7.66486	-$6.290606	-$9.100202
Income from continuing operations
Net other income	$0.225265	-$2.49455	$0.240383	$1.564605
EBIT	-$9.202863	-$7.66486	-$6.290606	-$9.100202
Income before tax	-$8.977598	-$10.15941	-$6.050223	-$7.535597
Income tax expense			$0.10282
Minority interest
Net income
Net income	-$8.977598	-$10.15941	-$6.153043	-$7.535597
Income (for common shares)	-$8.977598	-$10.15941	-$6.153043	-$7.535597

(in millions USD)	2021	2020	2019
Revenue
Total revenue	$2.547406	$1.957362	$2.092032
Cost of revenue	$9.624386	$3.94074	$0.458436
Gross profit	-$7.07698	-$1.983378	$1.633596
Operating activities
Research & development	$15.449001	$20.401595	$20.020959
Selling, general & administrative	$15.92617	$15.993227	$11.552496
Total operating expenses	$40.999557	$40.335562	$32.031891
Operating income	-$38.452151	-$38.3782	-$29.939859
Income from continuing operations
Net other income	$13.649774	$9.159102	-$5.162363
EBIT	-$38.452151	-$38.3782	-$29.939859
Income before tax	-$24.802377	-$29.219098	-$35.102222
Income tax expense	$0.086692	-$0.524057	$0.028793
Minority interest
Net income
Net income	-$24.889069	-$28.695041	-$35.131015
Income (for common shares)	-$24.889069	-$28.695041	-$35.131015

Quarterly
Annual

XSLX

(in millions USD)	29 Jun 2022	30 Mar 2022	30 Dec 2021	29 Sep 2021
Net income	-$8.977598	-$10.15941	-$6.153043	-$7.535597
Operating activities
Depreciation	$0.101399	$0.117836	$0.135626	$0.145088
Change in accounts receivable	-$0.244855	-$0.025589	$0.416911	-$0.580012
Changes in inventory	$0.137024	$0.077222	$0.121738	-$0.214097
Total cash flows from operations	-$6.261131	-$6.981163	-$4.385709	-$7.357588
Investing activities
Capital expenditures	-$0.048325	-$0.048325	-$0.048325	-$0.048325
Investments
Other cash flows from investing
Total cash flows from investing	-$0.048325	-$0.048325	-$0.018023	-$0.018023
Financing activities
Dividends paid
Net borrowings	-$0.08026	-$0.102454	-$0.110264	-$0.110264
Other cash flows from financing	-$0.141339	-$0.290961	$0.224337	$0.224337
Total cash flows from financing	-$0.221599	-$0.393415	$0.114073	-$0.110264
Effect of exchange rate
Change in cash and equivalents	-$6.531055	-$7.374578	-$4.289659	-$7.467852

(in millions USD)	2021	2020	2019
Net income	-$24.889069	-$28.695041	-$35.131015
Operating activities
Depreciation	$0.634553	$0.730624	$0.60125
Change in accounts receivable	-$0.401963	$0.253491	-$0.133153
Changes in inventory	-$0.640605	-$0.220822	-$0.359908
Total cash flows from operations	-$27.11277	-$29.449442	-$23.995264
Investing activities
Capital expenditures	-$0.110987	-$0.308478	-$0.203169
Investments
Other cash flows from investing
Total cash flows from investing	-$0.164081	-$0.341767	-$0.243501
Financing activities
Dividends paid
Net borrowings	-$0.491331	-$8.324437	-$0.513137
Other cash flows from financing	-$0.031034	$0.387887	$0.387887
Total cash flows from financing	$65.878358	$37.434236	$20.288789
Effect of exchange rate
Change in cash and equivalents	$38.601507	$7.643027	-$3.949976

Recent institutional transactions

Quarter	Shareholder	Change	Shares owned Shares	Value(in thousands USD)
2023 Q1	Marshall Wace, LL.P.	Sold out	10,834	$315,811
2019 Q4	Ladenburg Thalmann Financial Services Inc	+370.37%	127	$0
2017 Q2	Virtu Kcg	Opened	108,132	$149

Quarter

Shareholder

Change

Shares owned

Value(in thousands USD)

2023 Q1

Marshall Wace, LL.P.

Sold out

10,834

$315,811

2019 Q4

Ladenburg Thalmann Financial Services Inc

+370.37%

127

2017 Q2

Virtu Kcg

Opened

108,132

$149

Sign up for free

This feature is available only for signed-in users.

Already have an account?Sign in.

What symbols do you want to compare NVCN with?
Please separate symbols by ','

Pardon the interruption.

You've browsed 3 companies this week,
let's make this official

Already have an account? Sign in

"A killer stock screener."

— Berry M., Switzerland

Give wallmine a try – it's free.

Neovasc Inc (NVCN) Stock Price History – wallmine.com (2024)

Tuesday, 11 April 2023

Monday, 6 March 2023

Tuesday, 30 August 2022

Thursday, 28 July 2022

Friday, 4 February 2022

Tuesday, 9 November 2021

Tuesday, 10 August 2021

Thursday, 3 June 2021

Tuesday, 25 May 2021

Thursday, 13 May 2021

Thursday, 6 May 2021

Friday, 16 April 2021

Thursday, 11 March 2021

Thursday, 4 March 2021

Tuesday, 2 March 2021

Friday, 5 February 2021

Tuesday, 2 February 2021

Tuesday, 19 January 2021

Friday, 15 January 2021

Tuesday, 5 January 2021

Monday, 4 January 2021

Sunday, 3 January 2021

Friday, 1 January 2021

Thursday, 24 December 2020

Friday, 18 December 2020

Thursday, 17 December 2020

Tuesday, 15 December 2020

Monday, 14 December 2020

Thursday, 10 December 2020

Tuesday, 8 December 2020

Sunday, 6 December 2020

Notable SEC filings of Neovasc IncAll filingsLast yearly filingFilter

Recent call transcripts of Neovasc Inc

1,860 people own Neovasc Inc on Robinhood

Overall analyst rating

Price target

Neovasc Inc executives

Neovasc Incwww.neovasc.com

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

Recent institutional transactions

Sign up for free

This feature is available only for signed-in users.

What symbols do you want to compare NVCN with?Please separate symbols by ','

Pardon the interruption.

You've browsed 3 companies this week, let's make this official

"A killer stock screener."

Notable SEC filings of Neovasc Inc
All filingsLast yearly filingFilter

What symbols do you want to compare NVCN with?
Please separate symbols by ','

You've browsed 3 companies this week,
let's make this official